SGT represented a certified class of over 3,100 individuals who were patients of defendant Griffin Hospital from between September 2008 and May 2014 and received insulin administered via multi-dose insulin pens and obtained a $1 million settlement on behalf of the Class. The certified class alleged they suffered damages and emotional distress upon learning, via letter, that they had potentially been exposed to blood-borne pathogens as a result of at least eleven Griffin Hospital employees or agents improperly using multi-dose insulin pens.
The complaint alleged that the types of misuse include using a single pen on multiple patients, using a pen prescribed for a specific patient for whom it was not prescribed, drawing insulin from a pen prescribed for a specific patient into a separate syringe and administering the insulin to another patient, or removing the patient identification label affixed to a pen and then administering insulin from the pen to other patients. The court certified the proposed class of individuals on November, 23, 2020.
On February 22, 2024 the Court approved a $1 million settlement for the class.
The case is Diaz v. Griffin Hospital, No. UWYCV156029965S, and is pending before Hon. Linda Lager of the Connecticut Superior Court, Judicial District of Waterbury.
